

*Disclaimer :*

*The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.*

**M.7787 - PANASONIC HEALTHCARE / BAYER'S DIABETES CARE BUSINESS**

**SECTION 1.2**

**Description of the concentration**

1. The Commission has received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (the “EUMR”). On 22 of October, Panasonic Healthcare Holdings Co., Ltd. (“PHCHD”), holding company of Panasonic Healthcare (“PHC”), notified its intention to acquire sole control of Bayer AG’s diabetes care business (“BDC”) within the meaning of the EUMR.
2. The areas of activities of the undertakings concerned by the notified concentration are as follows:
  - KKR – global alternative asset manager and provider of financial advisory services;
  - PHCHD – holding company;
  - PHC – development, manufacture and sale of in vitro diagnostic devices and life science devices and services.
  - BDC – distribution of blood glucose monitoring systems.